COBLIXRA
DEAD

Serial Number

90606004

Owner

Bristol-Myers Squibb Company

Attorney

Xiomara Triana

Filing Date

Mar 26, 2021

Add to watchlist:

No watchlists yet
View on USPTO

COBLIXRA Trademark

Serial Number: 90606004

COBLIXRA is a trademark filed by Bristol-Myers Squibb Company on March 26, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Bristol-Myers Squibb Company (57 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

March 26, 2021

Registration Date

Not Registered

Published for Opposition

December 6, 2022

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 9, 2026 MAB6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 9, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 9, 2026 ABN6
ABANDONMENT - NO USE STATEMENT FILED
Mar 9, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 10, 2025 EXRA
SOU EXTENSION 5 GRANTED
Dec 10, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 10, 2025 AITU
SOU EXTENSION 5 FILED
Jun 24, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
Jun 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 4 GRANTED
Jan 7, 2025 EX4G
SOU EXTENSION 4 FILED
Jan 7, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 7, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 29, 2024 EXRA
SOU EXTENSION 3 GRANTED
Jul 29, 2024 EX3G
SOU EXTENSION 3 FILED
Jul 29, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 29, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 5, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jan 3, 2024 EX2G
SOU EXTENSION 2 FILED
Jan 3, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 3, 2024 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 15, 2023 EXRA
SOU EXTENSION 1 GRANTED
Jul 13, 2023 EX1G
SOU EXTENSION 1 FILED
Jul 13, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 13, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 31, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 6, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 6, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 16, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 31, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 31, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 31, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 31, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 31, 2022 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
May 3, 2022 GNFN
FINAL REFUSAL E-MAILED
May 3, 2022 GNFR
FINAL REFUSAL WRITTEN
May 3, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 6, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 6, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 6, 2022 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Oct 8, 2021 GPRN
PRIORITY ACTION E-MAILED
Oct 8, 2021 GPRA
PRIORITY ACTION WRITTEN
Oct 8, 2021 CPRA
ASSIGNED TO EXAMINER
Oct 5, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 2, 2021 NWOS
NEW APPLICATION ENTERED
Mar 30, 2021 NWAP